203. 22q11.2 deletion syndrome
3 clinical trials, 3 drugs (DrugBank: 0 drug) 0 gene, 0 pathway
Searched query = "22q11.2 deletion syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04639960 (ClinicalTrials.gov) | September 29, 2017 | 3/11/2020 | Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome | Effects of Modulation of the Dopaminergic System Using Risperidone on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome | 22q11.2 Deletion Syndrome | Drug: Risperdal;Drug: Placebo | University of Geneva, Switzerland | NULL | Recruiting | 11 Years | 25 Years | All | 30 | N/A | Switzerland |